CoChat

Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine the relative contributions of basal hyperglycemia (BHG) versus postprandial hyperglycemia (PPHG) before and after treatment intensification in patients with glycated hemoglobin A1c (A1C) >7.0% while on prior oral therapy. RESEARCH DESIGN AND METHODS: Self-measured, plasma-referenced glucose profiles and A1C values were evaluated from participants in six studies comparing systematically titrated insulin glargine with an alternative regimen (adding basal, premixed, or prandial insulin, or increasing oral agents). Hyperglycemic exposure (>100 mg/dL [5.6 mmol/L]) as a result of BHG versus PPHG was calculated. RESULTS: On prior oral therapy, 1,699 participants (mean age 59 years, diabetes duration 9 years) had mean fasting plasma glucose (FPG) of 194 mg/dL (10.8 mmol/L), and mean A1C was 8.7%. BHG contributed an average of 76–80% to hyperglycemia over the observed range of baseline A1C levels. Adding basal insulin for 24 or 28 weeks lowered mean FPG to 117 mg/dL (6.5 mmol/L), A1C to 7.0%, and BHG contribution to 32–41%. Alternative regimens reduced FPG to 146 mg/dL (8.1 mmol/L), A1C to 7.1%, and the contribution of BHG to 64–71%. BHG contributions for patients with A1C averaging 7.6–7.7% were 76% at baseline and 34 and 68% after adding basal insulin or other therapies, respectively. CONCLUSIONS: When A1C is >7.0% despite oral therapy, BHG routinely dominates exposure. Intensified therapy reduces A1C and changes this relationship, but BHG amenable to further intervention still accounts for one-third of total hyperglycemia after basal insulin treatment and two-thirds after alternative methods.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-0632

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A: Baseline seven-point glucose profiles by A1C category. B: Relative contributions of BHG and PPHG to overall hyperglycemia by A1C category at baseline. C: The seven-point glucose profiles by A1C category at week 24 or 28. D: Relative contributions of BHG and PPHG to overall hyperglycemia by A1C category at week 24 or 28.
Figure 1 A: Baseline seven-point glucose profiles by A1C category. B: Relative contributions of BHG and PPHG to overall hyperglycemia by A1C category at baseline. C: The seven-point glucose profiles by A1C category at week 24 or 28. D: Relative contributions of BHG and PPHG to overall hyperglycemia by A1C category at week 24 or 28.CC BY-NC-ND · PubMed Central
Figure 2 A: The seven-point glucose profiles for patients on basal insulin versus other treatments at week 24 or 28. B: Relative contributions of BHG and PPHG to overall hypoglycemia by A1C category after 24 or 28 weeks of basal insulin treatment. C: Relative contributions of BHG and PPHG to overall hyperglycemia by A1C category after 24 or 28 weeks of treatment with insulin lispro, premixed insulin, or OAD intensification.
Figure 2 A: The seven-point glucose profiles for patients on basal insulin versus other treatments at week 24 or 28. B: Relative contributions of BHG and PPHG to overall hypoglycemia by A1C category after 24 or 28 weeks of basal insulin treatment. C: Relative contributions of BHG and PPHG to overall hyperglycemia by A1C category after 24 or 28 weeks of treatment with insulin lispro, premixed insulin, or OAD intensification.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

Items 101–200 of 225

Metadata

Authors
Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J.
Affiliations
  • Oregon Health & Science University (US)
  • Emory University (US)
  • Sanofi (United States) (US)
  • Medpace (United States) (US)
  • Dallas Diabetes and Endocrine Center, Dallas, Texas
Corresponding author
Riddle, Matthew
Venue
Diabetes Care
Published
2011-11-14
Volume
34
Issue
12
Pages
2508-2514
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2103903409
Cited by
219
References
20
Citations by year
2026: 7 · 2025: 10 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 13 · 2019: 22 · 2018: 13 · 2017: 17 · 2016: 18 · 2015: 28 · 2014: 22 · 2013: 29 · 2012: 8
FWCI
16.01
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Medpace
  • MannKind Corporation
  • European Foundation for the Study of Diabetes
  • Novo Nordisk
  • National Institutes of Health (UL1TR000454)
  • National Center for Advancing Translational Sciences
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, postprandial hyperglycemia, HbA1c, treatment intensification, insulin glargine, basal insulin, oral antidiabetic drugs, fasting blood glucose, glycemic control
MeSH terms
Isophane Insulin, Human, Insulin Glargine, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Insulin, Isophane, Male, Middle Aged, Randomized Controlled Trials as Topic, Treatment Outcome, Insulin, Long-Acting, Insulin, Regular, Human

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.